Matches in SemOpenAlex for { <https://semopenalex.org/work/W113706255> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W113706255 endingPage "8" @default.
- W113706255 startingPage "253" @default.
- W113706255 abstract "Daily and intermittent continuous intravenous infusions [by gravity drip, (IVG) or infusion pump, (IVP)] and intermittent short-time intravenous drip infusion of 5-FU were carried out on advanced cancer patients. The MTD and dose-limiting toxicity were investigated in relation to the plasma concentrations of 5-FU determined by HPLC. Responses in eleven patients receiving IVG administration daily at 8-21 mg/kg/day were NC, but those given 5-FU alone showed no adverse reactions. Plasma concentrations were too low to be determined. In 9 patients receiving IVG or IVP administration weekly at 60 mg/kg for 24 hr, 1 of the 5 evaluable patients showed reduced hepatic metastatic lesions. One of 4 patients receiving IVP administration weekly at 120 mg/kg for 48 hr showed a disappearance of metastatic lesions in the skeletal muscle, but bone marrow suppression was observed as dose-limiting toxicity. Pharmacokinetics were more stable in IVP than in IVG with less individual difference in the plasma concentrations. Among the outpatients receiving short-time iv, IVG administration once or twice a week, 2 patients given weekly administrations at 20 mg/kg for 60 min showed slight adverse reactions. In 6 patients given high-dose administrations, bone marrow suppression was observed. When pharmacokinetics in the patients given 5-FU for 60 min were compared between the IVG and IVP groups, there were individual differences in plasma concentrations, but the differences were not significant. It was concluded from above results that the following practical dose schedules would be recommendable: 60 mg/kg for 24hr/week by IVP for inpatients and 20 mg/kg for 60 min/week by IVG for outpatients." @default.
- W113706255 created "2016-06-24" @default.
- W113706255 creator A5003917214 @default.
- W113706255 creator A5005041113 @default.
- W113706255 creator A5011606344 @default.
- W113706255 creator A5026513362 @default.
- W113706255 creator A5027062618 @default.
- W113706255 creator A5030715946 @default.
- W113706255 creator A5032982366 @default.
- W113706255 creator A5033764996 @default.
- W113706255 creator A5060404237 @default.
- W113706255 creator A5076674260 @default.
- W113706255 date "1990-02-01" @default.
- W113706255 modified "2023-09-25" @default.
- W113706255 title "[Clinical reevaluation of continuous intravenous infusion of 5-fluorouracil--plasma concentrations and clinical dose by continuous intravenous and 60-min infusions]." @default.
- W113706255 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2301952" @default.
- W113706255 hasPublicationYear "1990" @default.
- W113706255 type Work @default.
- W113706255 sameAs 113706255 @default.
- W113706255 citedByCount "1" @default.
- W113706255 crossrefType "journal-article" @default.
- W113706255 hasAuthorship W113706255A5003917214 @default.
- W113706255 hasAuthorship W113706255A5005041113 @default.
- W113706255 hasAuthorship W113706255A5011606344 @default.
- W113706255 hasAuthorship W113706255A5026513362 @default.
- W113706255 hasAuthorship W113706255A5027062618 @default.
- W113706255 hasAuthorship W113706255A5030715946 @default.
- W113706255 hasAuthorship W113706255A5032982366 @default.
- W113706255 hasAuthorship W113706255A5033764996 @default.
- W113706255 hasAuthorship W113706255A5060404237 @default.
- W113706255 hasAuthorship W113706255A5076674260 @default.
- W113706255 hasConcept C112705442 @default.
- W113706255 hasConcept C126322002 @default.
- W113706255 hasConcept C127413603 @default.
- W113706255 hasConcept C188198153 @default.
- W113706255 hasConcept C197934379 @default.
- W113706255 hasConcept C2776694085 @default.
- W113706255 hasConcept C2780007613 @default.
- W113706255 hasConcept C2780456651 @default.
- W113706255 hasConcept C2911027401 @default.
- W113706255 hasConcept C29730261 @default.
- W113706255 hasConcept C3018112808 @default.
- W113706255 hasConcept C3020079912 @default.
- W113706255 hasConcept C42219234 @default.
- W113706255 hasConcept C71924100 @default.
- W113706255 hasConcept C78519656 @default.
- W113706255 hasConceptScore W113706255C112705442 @default.
- W113706255 hasConceptScore W113706255C126322002 @default.
- W113706255 hasConceptScore W113706255C127413603 @default.
- W113706255 hasConceptScore W113706255C188198153 @default.
- W113706255 hasConceptScore W113706255C197934379 @default.
- W113706255 hasConceptScore W113706255C2776694085 @default.
- W113706255 hasConceptScore W113706255C2780007613 @default.
- W113706255 hasConceptScore W113706255C2780456651 @default.
- W113706255 hasConceptScore W113706255C2911027401 @default.
- W113706255 hasConceptScore W113706255C29730261 @default.
- W113706255 hasConceptScore W113706255C3018112808 @default.
- W113706255 hasConceptScore W113706255C3020079912 @default.
- W113706255 hasConceptScore W113706255C42219234 @default.
- W113706255 hasConceptScore W113706255C71924100 @default.
- W113706255 hasConceptScore W113706255C78519656 @default.
- W113706255 hasIssue "2" @default.
- W113706255 hasLocation W1137062551 @default.
- W113706255 hasOpenAccess W113706255 @default.
- W113706255 hasPrimaryLocation W1137062551 @default.
- W113706255 hasRelatedWork W113706255 @default.
- W113706255 hasRelatedWork W18390515 @default.
- W113706255 hasRelatedWork W2029181049 @default.
- W113706255 hasRelatedWork W2051036097 @default.
- W113706255 hasRelatedWork W2073209900 @default.
- W113706255 hasRelatedWork W2354314574 @default.
- W113706255 hasRelatedWork W2364607478 @default.
- W113706255 hasRelatedWork W2433363021 @default.
- W113706255 hasRelatedWork W2469049851 @default.
- W113706255 hasRelatedWork W3029134410 @default.
- W113706255 hasVolume "17" @default.
- W113706255 isParatext "false" @default.
- W113706255 isRetracted "false" @default.
- W113706255 magId "113706255" @default.
- W113706255 workType "article" @default.